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Widespread use of incorrect PCR 
ramp rate negatively impacts 
multidrug-resistant tuberculosis 
diagnosis (MTBDRplus)
B. Derendinger1, M. de Vos1, R. R. Nathavitharana2, T. Dolby3, J. A. Simpson3, P. D. van 
Helden1, R. M. Warren1 & G. Theron1
The scale-up of rapid drug resistance testing for TB is a global priority. MTBDRplus is a WHO-endorsed 
multidrug-resistant (MDR)-TB PCR assay with suboptimal sensitivities and high indeterminate rates 
on smear-negative specimens. We hypothesised that widespread use of incorrect thermocycler ramp 
rate (speed of temperature change between cycles) impacts performance. A global sample of 72 
laboratories was surveyed. We tested 107 sputa from Xpert MTB/RIF-positive patients and, separately, 
dilution series of bacilli, both at the manufacturer-recommended ramp rate (2.2 °C/s) and the most 
frequently reported incorrect ramp rate (4.0 °C/s). Mycobacterium tuberculosis-complex DNA (TUB-
band)-detection, indeterminate results, accuracy, and inter-reader variability (dilution series only) were 
compared. 32 respondents did a median (IQR) of 41 (20–150) assays monthly. 78% used an incorrect 
ramp rate. On smear-negative sputa, 2.2 °C/s vs. 4.0 °C/s improved TUB-band positivity (42/55 vs. 32/55; 
p = 0.042) and indeterminate rates (1/42 vs. 5/32; p = 0.039). The actionable results (not TUB-negative 
or indeterminate; 41/55 vs. 28/55) hence improved by 21% (95% CI: 9–35%). Widespread use of incorrect 
ramp rate contributes to suboptimal MTBDRplus performance on smear-negative specimens and hence 
limits clinical utility. The number of diagnoses (and thus the number of smear-negative patients in 
whom DST is possible) will improve substantially after ramp rate correction.
There were ~10.4 million reported cases of tuberculosis (TB) and 1.7 million deaths from TB in 2016. Only 22% 
of the ~490 000 new cases of multidrug-resistant (MDR-) TB in 2016 were diagnosed1. Drug-susceptibility test-
ing (DST) has relied on culture for phenotypic and molecular testing (indirect testing)2. Earlier drug resistance 
diagnosis through rapid sputum testing (direct testing) can facilitate early effective treatment initiation3 and help 
render patients non-infectious4. This can disrupt transmission5; a key driver of MDR-TB6 that results in poor 
patient outcomes and substantial costs1,7.
GenoType MTBDRplus8 (Hain Lifescience, Germany) is a rapid PCR line probe assay for Mycobacterium 
tuberculosis-complex DNA (reported as TUB-band-positive) and rifampicin- and isoniazid-resistance. 
MTBDRplus is World Health Organization- (WHO)9 and Centers for Disease Control and Prevention-endorsed10. 
Many countries have incorporated MTBDRplus into national diagnostic algorithms11. MTBDRplus involves the 
amplification of regions within the M. tuberculosis genome and their colorimetric visualisation by hybridisation 
to membrane-bound probes. Despite the manufacturer’s recommendation for use in smear-negative specimens, 
evidence to support MTBDRplus in this context is relatively weak and heterogeneous, with studies describing 
sensitivities ranging from 40–100% and indeterminate rates ranging from 0.5–14.5%12–18. This limited data to 
support use in smear-negative specimens restricts MTBDRplus’s utility in high burden, HIV-endemic settings19. 
The WHO endorsement for direct MTBDRplus testing is hence for smear-positive specimens only20.
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The latest iteration of MTBDRplus (version 2) was designed to have improved sensitivity on specimens, irre-
spective of smear status, and culture isolates. MTBDRplus’s follow-on test for second-line resistance (MTBDRsl; 
Hain Lifescience, Germany) is based on similar principles and also WHO-endorsed9,16,21,22.
MTBDRplus requires thermocycling to amplify DNA. The manufacturer recommends a ramp rate (speed of 
temperature change between cycles) of ≤ 2.2 °C/s8, which the thermocycler they sell (the GTC-cycler) is capable 
of. Laboratories can use their own thermocyclers, however, these thermocyclers may have different default ramp 
rates or, in cheaper models, may not permit ramp rate to be changed. None of the studies in a recent systematic 
review and meta-analysis of MTBDRplus report ramp rate and few studies reported rates of TUB-band positiv-
ity16,23. If an assay is TUB-band-negative, susceptibility results cannot, per the manufacturer’s recommendation, 
be reported8 and studies that do not report TUB-band positivity rates do not provide a complete characterisation 
of test performance.
We hypothesised that suboptimal sensitivities and high indeterminate rates reported for MTBDRplus on 
smear-negative specimens12–17 were partly associated with incorrect ramp rate. If this phenomenon is widespread, 
it may explain a major limitation in the routine diagnosis of MDR-TB, for which MTBDRplus is the only com-
mercially available molecular assay. This could result in large numbers of possible MDR-TB diagnoses being 
missed, exacerbate diagnostic delay, and will have implications for diagnostic algorithms (e.g., confirmation of 
Xpert-indicated rifampicin-resistance, detection of rifampicin or isoniazid mono-resistance), clinical practice 
(e.g., detection of acquired resistance during treatment monitoring), and research studies (e.g., MDR-TB drug 
trials that need to rapidly screen patients).
Methods
Ethics statement. This study was approved by the Health Research Ethics Committee of Stellenbosch 
University (N09–11–296) and done in accordance with these relevant guidelines and regulations. Permission 
was granted by the institutional review board (IRB) to access anonymised residual specimens collected as part of 
routine diagnostic practice and thus patient informed consent was waived.
Survey of diagnostic and research laboratories. An invitation to an online survey was sent to 74 lab-
oratories using MTBDRplus identified from a recent systematic review and meta-analysis16, expert consultation, 
the Global Laboratory Initiative, the Global Health Delivery network, and FIND. We placed no restrictions on the 
type of facility or country that could respond. Initial non-responders were emailed at least a further three times. 
Questions included country, average number of MTBDRplus assays per month, primary purpose of the assay, 
specimen smear status, models of thermocyclers, whether the thermocycler permitted ramp rate to be changed, 
and the MTBDRplus ramp rate used (the full questions are listed in the supplement). Permission was obtained 
from respondents to use their anonymised data for publication.
Specimen collection and decontamination. 107 de-identified sputa consecutively submitted to an 
accredited government quality-assured (South African National Accreditation System) laboratory in Cape 
Town, South Africa were collected. Sputa were from patients with symptoms of TB who were, using a sep-
arate paired specimen, Xpert MTB/RIF (Xpert)-positive for TB and rifampicin-susceptible or -resistant. 
Sputa were decontaminated with NaOH-N-Acetyl-L-Cysteine (1% final concentration)24. Each decontami-
nated sediment had ~50 µl used for Auramine-O25 smear microscopy and, if the paired specimen was Xpert 
rifampicin-resistant, ~500 µl used for culture for DST. 52 sputa were smear-positive (26 Xpert-rifampicin resist-
ant, 26 Xpert-rifampicin susceptible) and 55 smear-negative (39 Xpert-rifampicin resistant, 16 Xpert-rifampicin 
susceptible). The sediments were stored at 4 °C for 2–3 days prior to transport to Stellenbosch University for 
DNA extraction.
Impact of thermocycler ramp rate on MTBDRplus performance in clinical specimens. DNA 
was extracted from sediments using the GenoLyse kit (Hain Lifescience, Germany)8. DNA was amplified using 
two ramp rates: the manufacturer-recommended ramp rate (2.2 °C/s), and 4.0 °C/s, the most frequently used 
incorrect ramp rate in the survey, using a CFX96 (Bio-Rad, United States), which was the only machine available 
with a customisable ramp rate. This instrument undergoes annual servicing and calibration by the manufacturer. 
Hybridisation was done with the GT-Blot 48 (Hain Lifescience, Germany)26. An experienced reader interpreted 
bands in a blinded manner.
Impact of thermocycler ramp rate on MTBDRplus performance in a dilution series. A drug-susceptible 
strain (H37Rv, ATCC 25618) and a phenotypically-confirmed clinical MDR strain (with known rpoB, katG, and 
inhA promoter SNPs) were grown to mid-exponential phase in Middlebrook 7H9 media (Becton Dickinson, 
United States) supplemented with Middlebrook Oleic Albumin Dextrose Catalase supplement (Becton 
Dickinson, United States). Colony counts after incubation on Middlebrook 7H10 media (Becton Dickinson, 
United States) for 21 days at 37 °C were done. This experiment was done in triplicate. MTBDRplus was done on 
dilutions of 102, 103 and 104CFU/ml in phosphate buffer with 0.025% Tween 80. 104CFU/ml corresponds approx-
imately to smear-positivity27 and the lower concentrations in the dilution series correspond to paucibacillary 
smear-negative disease (i.e., the patients we hypothesise ramp rate to impact the most). The CFX96 machine with 
ramp rates of 2.2 °C/s or 4.0 °C/s was used. An experienced reader interpreted bands in a blinded manner.
Assessment of inter-reader variability. MTBDRplus strips from the dilution series were interpreted by 
two experienced technicians in a blinded manner. Variability between readers (individual banding patterns, final 
diagnostic classifications) was assessed. When a strip is interpreted, a banding call determination is made if a 
specific band is present or absent; whereas a diagnostic call (susceptibility or resistance to rifampicin and/or iso-
niazid) is based on the overall banding pattern. Hence, banding patterns may change but not the diagnostic call. 
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Excluding the conjugate and amplification control bands, gene loci control bands, and including the TUB-band, 
gene-specific wildtype and mutant bands, there are 22 possible bands per strip that we included in our analysis for 
the comparison of banding pattern readability.
Classification of MTBDRplus results. A positive result for M. tuberculosis-complex DNA was defined 
as the presence of the TUB-band with the amplification and conjugation control bands. Sensitivity for M. 
tuberculosis-complex DNA was calculated using a paired MGIT960 liquid culture (Becton Dickinson, United 
States) result from the national laboratory as a reference standard. A strip was classified as indeterminate if the 
amplification or conjugate control bands were absent but any other bands were present. A drug indeterminate 
result was defined as the absence of any locus control band (rpoB, katG and inhA) on a TUB-band-positive strip. 
A result was classified as actionable if the strip was TUB-band-positive and not indeterminate for any drugs.
Statistical analyses. The two sample test of proportion was used for comparisons between proportions, 
and McNemar’s test was used to calculate differences in sensitivity or indeterminate rates across ramp rates 
for paired data. We used the percent improvement in actionable results (calculated from our clinical specimen 
experiment, 21%) to estimate the number of additional TUB-band-positive diagnoses (and MDR-TB diagno-
ses) in survey respondents who said they tested smear-negative specimens. For this calculation, we assumed 1) 
the volume of assays done by the respondent was evenly spread across input material types (e.g., a respondent 
doing 100 MTBDRplus assays per month does ~33 smear-positive, smear-negative, and isolates; we unfortu-
nately did not retrieve specific data on the monthly volume of smear-negative specimens only), 2) the MDR-TB 
prevalence in smear-negative specimens corresponded to the overall WHO estimate for the respondent’s coun-
try, and 3) ramp rate changes would equally affect resistance and susceptibility detection. We used GraphPad 
Prism version 6.0 (GraphPad Software) and Stata version 14 (StataCorp) software. All statistical tests are 2-sided 
at α = 0.05.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Results
Survey. Laboratory respondents were geographically diverse and often tested smear-positive and smear-neg-
ative specimens, as well as culture isolates (Fig. 1a,b). Our survey response rate was 32/72 (44%). Respondents 
did a median [interquartile range (IQR)] of 41 (20–150) MTBDRplus assays per month (Fig. 1c). 18/32 (56%) of 
Figure 1. Survey results showing breakdowns of (a) the geographical locations of laboratory survey 
respondents, (b) type of input material used (smear status and/or culture isolate) for MTBDRplus, (c) amount of 
MTBDRplus assays done per laboratory each month and (d) ramp rates used by respondents
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 Country
MTBDRplus/
month
MTBDRplus 
use
MTBDRplus sample 
type
MTBDRsl/
month
MTBDRsl 
use
MTBDRsl 
sample type
Other 
LPAs
Thermocycler 
manufacturer Thermocycler
Ramp 
rate (°C/s)
Customisable 
ramp rate
Pre-
screening 
Xpert 
MTB/RIF
Africa [14 laboratories; median (IQR) of 46 (20–241) MTBDRplus assays per month]
South 
Africa 900 Diagnosis
Smear-positive, smear-
negative, isolates 50 Diagnosis
Smear-positive, 
smear-negative, 
isolates
N/A Applied Biosystems SimpliAmp 4.0 Yes Yes
Swaziland 350 Diagnosis, research
Smear-positive, 
isolates 0
Diagnosis, 
research
Smear-positive, 
isolates N/A
Applied 
Biosystems
2720 Thermal 
Cycler 2.7 No Yes
South 
Africa 245 Diagnosis
Smear-positive, 
isolates 0 Diagnosis
Smear-positive, 
isolates
CM/
AS
Applied 
Biosystems ABI 4.0 Yes Yes
Kenya 240 Diagnosis, research
Smear-positive, smear-
negative 0 Research Smear-positive
CM/
AS
Applied 
Biosystems
GeneAmp 
9700 2.3 Yes Yes
South 
Africa 150
Diagnosis, 
research Isolates 15 Diagnosis Isolates N/A
Applied 
Biosystems ABI 6.0 Yes Yes
Ethiopia 75 Diagnosis, research
Smear-positive, 
isolates 60
Diagnosis, 
research
Smear-positive, 
smear-negative, 
isolates
CM/
AS
Applied 
Biosystems
2720 Thermal 
Cycler 2.7 No Yes
South 
Africa 50 Diagnosis
Smear-positive, smear-
negative, isolates 45 Diagnosis
Smear-positive, 
smear-negative, 
isolates
CM Applied Biosystems
Proflex PCR 
system 4.0 Yes No
Nigeria 42 Diagnosis, research
Smear-positive, smear-
negative, isolates 27
Diagnosis, 
research
Smear-positive, 
smear-negative, 
isolates
CM/
AS
Applied 
Biosystems
2720 Thermal 
Cycler 2.7 No Yes
South 
Africa 40
Diagnosis, 
research Isolates 0
Diagnosis, 
research Isolates CM
Applied 
Diagnosis Various 4.0 Yes Yes
Nigeria 25 Diagnosis
Smear-positive, 
smear-negative, 
isolates
35 Diagnosis
Smear-positive, 
smear-negative, 
isolates
CM Hain Lifescience
GTQ-cycler 
96 2.2 Yes Yes
Cameroon 20 Diagnosis, research
Smear-positive, 
smear-negative 20
Diagnosis, 
research
Smear-positive, 
smear negative
CM/
AS
Applied 
Biosystems
GeneAmp 
9700 2.2 Yes Yes
Botswana 20 Diagnosis, research
Smear-positive, 
isolates 20
Diagnosis, 
research
Smear-positive, 
isolates CM
Hain 
Lifescience
GTQ-cycler 
96 2.2 Yes No
South 
Africa 20
Diagnosis, 
research
Smear-positive, smear-
negative, isolates 0
Diagnosis, 
research
Smear-positive, 
smear-negative, 
isolates
CM Bio-Rad Various 4.0 No No
Côte 
d’Ivoire 14
Diagnosis, 
research
Smear-positive, 
isolates 4
Diagnosis, 
research
Smear-positive, 
isolates N/A
Applied 
Biosystems
2720 Thermal 
Cycler 2.7 No Yes
Asia [7 laboratories; median (IQR) of 150 (15–256) MTBDRplus assays per month]
Azerbaijan 750 Diagnosis, research
Smear-positive, 
isolates 0
Diagnosis, 
research
Smear-positive, 
isolates N/A Unknown Unknown 12.0 No Yes
Kyrgyzstan 256 Diagnosis Smear-positive, smear-negative, isolates 37 Diagnosis Smear-positive N/A Biometra Tprofessional 3.0 Yes Yes
Bangladesh 150 Diagnosis Smear-positive, smear-negative, isolates 120 Diagnosis
Smear-positive, 
smear-negative, 
isolates
N/A Applied Biosystems
2720 Thermal 
Cycler 2.7 No Yes
India 150 Diagnosis Smear-positive, smear-negative, isolates 0 Diagnosis
Smear-positive, 
isolates CM Bio-Rad
Thermal 
Cycler T100 4.0 No No
Pakistan 30 Diagnosis, research
Smear-positive, 
smear-negative, 
isolates
2 Research Isolates CM/AS
Hain 
Lifescience
GTQ-cycler 
96 2.2 Yes Yes
Myanmar 15 Diagnosis Smear-positive, smear-negative, isolates 10 Diagnosis
Smear-positive, 
smear-negative, 
isolates
N/A Applied Biosystems
2720 Thermal 
Cycler 2.7 No Yes
Thailand 5 Diagnosis Smear-positive, smear-negative 0 Research Isolates N/A
Applied 
Biosystems
2720 Thermal 
Cycler 2.7 No No
Europe [10 laboratories; median (IQR) of 35 (23–64) MTBDRplus assays per month]
Denmark 90 Diagnosis, research
Smear-positive, smear-
negative, isolates 5
Diagnosis, 
research
Smear-positive, 
isolates
CM/
AS
Applied 
Biosystems SimpliAmp 4.0 Yes No
Belarus 75 Diagnosis Smear-positive, smear-negative, isolates 80 Diagnosis
Smear-positive, 
smear-negative, 
isolates
CM/
AS
Applied 
Biosystems
2720 Thermal 
Cycler 2.7 No Yes
Moldova 60 Diagnosis, research
Smear-positive, 
smear-negative, 
isolates
24 Diagnosis, research
Smear-positive, 
smear-negative N/A
Hain 
Lifescience
GTQ-cycler 
96 2.2 Yes Yes
Belgium 50 Diagnosis, research
Smear-positive, 
isolates 30
Diagnosis, 
research
Smear-positive, 
isolates Nipro Biometra Tprofessional 3.0 Yes Yes
Belarus 40 Diagnosis Smear-positive, isolates 0 Diagnosis
Smear-positive, 
isolates CM
Applied 
Biosystems
2720 Thermal 
Cycler 2.7 No Yes
Germany 30 Diagnosis
Smear-positive, 
smear-negative, 
isolates
10 Diagnosis
Smear-positive, 
smear-negative, 
isolates
N/A Hain Lifescience
GTQ-cycler 
96 2.2 Yes Yes
Denmark 25 Diagnosis, research
Smear-positive, smear-
negative, isolates 4
Diagnosis, 
research
Smear-positive, 
smear-negative, 
isolates
CM/
AS
Applied 
Biosystems SimpliAmp 4.0 Yes No
Continued
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respondents used MTBDRplus for both routine diagnosis and research. Critically, 25/32 (78%) of respondents 
used an incorrect ramp rate (Fig. 1d), ranging from 2.3–12.0 °C/s. Of respondents that tested smear-negative 
specimens (21/32; 66%), 16/21 (76%) used an incorrect ramp rate. Stratified by continent, 3/14 (21%) African, 1/7 
(14%) Asian, 3/10 (30%) European and 0/1 (0%) South American laboratories used the correct ramp rate. 19/32 
(59%) of respondents indicated that they could set the correct ramp rate by adjusting their thermocycler, whereas 
the remainder did not use thermocyclers with customisable ramp rates (Table 1). 10/32 (31%) laboratories did 
MTBDRplus only and 22/32 (69%) did MTBDRplus and MTBDRsl.
Performance of MTBDRplus at different ramp rates on clinical specimens. In smear-positive spec-
imens (n = 52), TUB-band detection was 100% irrespective of ramp rate, whereas in smear-negative specimens 
TUB-band detection was 76% (42/55) at 2.2 °C/s and 58% (32/55) at 4.0 °C/s (p = 0.042). Smear-positive spec-
imens had no indeterminate results. For smear-negative specimens, of the 42 TUB-band positives at 2.2 °C/s, 
1 (2%) was indeterminate for isoniazid whereas at 4.0 °C/s, 5/32 (16%) TUB-positive specimens were inde-
terminate for isoniazid (p = 0.093) (Table 2). There were no indeterminate results for rifampicin in the clini-
cal specimens, regardless of ramp rate. Thus, for smear-negative specimens, an actionable result could not be 
generated at 2.2 °C/s for 14/55 (13 TUB-negatives + 1 indeterminate result for isoniazid; 25%) specimens and 
28 (23 TUB-negatives + 5 indeterminate results for isoniazid; 51%) specimens at 4.0 °C/s (p = 0.006). Hence, 
ramp rate correction resulted in a 21% (95% CI: 9–35%; p < 0.0001) increase in the number of diagnoses in 
smear-negative specimens. If we apply this increase to the volume of testing reported by our 16 respondent lab-
oratories that test smear-negative specimens, we would expect an additional ~89 TUB-band positive tests per 
month in smear-negative specimens that, at each respondent’s local MDR-TB prevalence, should translate into 
~7 additional MDR-TB diagnoses overall amongst the respondents.
Performance of MTBDRplus at different ramp rates on dilution series of bacilli. Each of the three 
technical replicates for each strain in the dilution series (102, 103 and 104CFU/ml) were TUB-band-positive and 
there were no indeterminate results, irrespective of ramp rate. At 4.0 °C/s, the drug-susceptible strain gave a 
false-positive rifampicin-resistance result in a 102CFU/ml replicate, however, at higher concentrations all results 
were true-susceptible. Overall, bands at 2.2 °C/s were subjectively interpreted as being darker, clearer, and more 
distinct than those at 4.0 °C/s by the experienced readers.
Assessment of inter-reader agreement on dilution series. Banding and diagnostic calls differed 
between readers and were most pronounced at 102CFU/ml (Table 3). Of the 198 possible non-control bands in 
the dilution series experiment for the drug-susceptible strain, readers disagreed on 1% (2/198) of bands at 4.0 °C/s 
but none at 2.2 °C/s (p = 0.156). For the MDR strain, there were 6/198 (3%) band differences between readers 
at 4.0 °C/s and 1/198 (0.5%) differences at 2.2 °C/s (p = 0.057). At 4.0 °C/s, one reader reported one replicate of 
the MDR strain as false-susceptible to rifampicin at 102CFU/ml and the same strain as TUB-band-negative at 
103CFU/ml (the other reader read both these strips correctly).
 Country
MTBDRplus/
month
MTBDRplus 
use
MTBDRplus sample 
type
MTBDRsl/
month
MTBDRsl 
use
MTBDRsl 
sample type
Other 
LPAs
Thermocycler 
manufacturer Thermocycler
Ramp 
rate (°C/s)
Customisable 
ramp rate
Pre-
screening 
Xpert 
MTB/RIF
France 25 Diagnosis Smear-positive, smear-negative, isolates 17 Diagnosis
Smear-positive, 
smear-negative, 
isolates
CM/
AS, 
NTM-
DR
Bio-Rad Various 4.0 Yes No
Italy 15 Diagnosis, isolates
Smear-positive, 
isolates 15
Diagnosis, 
research
Smear-positive, 
isolate N/A
Hain 
Lifescience
GTQ-cycler 
96 2.2 Yes No
Spain 10 Diagnosis Smear-positive, smear-negative, isolates 2 Diagnosis
Smear-positive, 
smear-negative, 
isolates
Inno-
Lipa
Applied 
Biosystems Various 4.0 Yes No
South America (1 laboratory; 20 MTBDRplus assays per month)
Brazil 20 Diagnosis, research
Smear-positive, smear-
negative, isolates 0
Diagnosis, 
research
Smear-positive, 
smear-negative, 
isolates
MOTT 
ID Bio-Rad C1000 Touch 5.0 Yes Yes
Overall [32 laboratories; median (IQR) of 41 (20–150) MTBDRplus assays per month]
3987 632
16/32 
respondents test 
smear-negative 
specimens and 
are hence likely 
affected by 
incorrect ramp 
rate usage
7/32 used 
the correct 
ramp rate
20/32 have a 
customisable 
ramp rate
22/32 use 
Xpert as a 
pre-screen
Table 1. Answers to survey questions stratified by continent. LPA - Line probe assay; HCV – HCV Genotype 
2.0 Assay (LiPA); CM-Genotype Mycobacterium CM Ver 2.0; NTM-DR – GenoType NTM-DR Ver 1.0; AS - 
Genotype Mycobacterium AS Ver 1.0; IQR - Interquartile Range; Xpert – Xpert MTB/RIF assay. Survey questions 
are in the supplement. Text in bold refers to laboratories using the manufacturer-recommended ramp rate.
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Discussion
Our key findings are: 1) the vast majority of survey respondents, who are globally diverse and do a large vol-
ume of MTBDRplus assays, use an incorrect ramp rate and this, 2) decreases sensitivity for TB (and hence pre-
cludes resistance detection), 3) increases indeterminate rates in smear-negative specimens, and 4) likely increases 
false-resistance calls and banding pattern disagreement between readers. These findings are of clinical relevance 
as most respondents used this assay routinely, indicating that incorrect ramp rate usage is likely affecting patient 
diagnoses.
To the best of our knowledge, ours is the first evaluation of ramp rate on commercial assay performance in 
the clinical diagnostics literature. Ramp rate has been previously-documented to be important: techniques such 
as “slowdown PCR”, which are optimised to amplify GC-rich regions with complex secondary structures, use 
different rates for heating and cooling to improve primer annealing and amplification. Here, ramp rate is critical 
for the performance of this technique28. As M. tuberculosis is GC-rich and rpoB can form secondary structures29, 
it is possible that slower ramp rates help reduce secondary structure formation (e.g., during the transition from 
denaturation to annealing phases) and thereby result in better detection.
Our survey found the majority of laboratories to use an incorrect ramp rate, despite a lower ramp rate being 
recommended. About half of respondents could change the ramp rate. Together, this illustrates that incorrect 
ramp rate usage is likely widespread but, importantly, easily fixable without the purchase of new thermocyclers, 
which may be prohibitively expensive in high burden settings.
TUB-band detection on smear-negative sputa failed more frequently at incorrect ramp rates. As this band 
is required before a susceptibility result is reported, drug resistant diagnoses are more likely to be missed at the 
incorrect ramp rate. Differences in ramp rate may hence partly explain previously reported variation in perfor-
mance in smear-negative specimens12–15,17 however, we only received responses to our queries regarding ramp 
rate from two studies in the systematic review who used smear-negative specimens.
Although Xpert is often the initial first-line test for rifampicin-resistance, MTBDRplus is used for MDR-TB in 
several high TB-burden countries and to confirm isoniazid-susceptibility. Isoniazid can be included in the new 
WHO-endorsed MDR-TB second-line regimen30. In response to the WHO’s endorsement of the regimen, labo-
ratories are scaling-up MTBDRsl capacity for second-line drug resistance testing. MTBDRsl is thus of increasing 
importance, however, we did not include MTBDRsl for reasons of cost and feasibility. MTBDRsl is nevertheless 
similar to MTBDRplus, has the same recommended ramp rate, and is hence likely similarly adversely impacted. 
We will validate this in future.
We did not assess the impact of several ramp rates or thermocyclers for reasons of cost and limited clinical 
specimens, but chose to use the most frequently reported incorrect ramp rate and a machine commonly used 
in our setting (the survey results showed a large diversity in thermocycler models used, with no predominant 
Smear 
microscopy status
Ramp rate 
(°C/s)
TUB-band 
positive (%)
Determinate 
(%)
Indeterminate 
(%)
Positive n = 52
4.0 52/52 (100) 52/52 (100) 0/52 (0)
2.2* 52/52 (100) 52/52 (100) 0/52 (0)
Negative n = 55
4.0 32/55 (58) 27/32 (84) 5/32 (16)
2.2* 42/55 (76) (p = 0.042)
41/42 (98) 
(p = 0.164)
1/42 (2) 
(p = 0.039)
Table 2. Performance of Genotype MTBDRplus at different ramp rates for the detection of M. tuberculosis-
complex DNA (TUB-band), stratified by smear status, when done directly on sputa from Xpert MTB/RIF-
positive patients. Genolysed extract from each specimen was tested at each ramp rate. TUB-band detection and 
the rate of indeterminates worsened in smear-negative specimens with use of the incorrect ramp rate. P-values 
are for comparisons between ramp rates for smear-negative specimens. *Manufacturer-recommended ramp rate.
Ramp rate (°C/s)
2.2 (%) 4.0 (%)
Banding calls
Different band calls between 
readers for susceptible strain 0/198
* (0) 2/198 (1) (p = 0.156)
Different band calls between 
readers for resistant strain 1/198 (0.5)
6/198 (3) 
(p = 0.057)
Diagnostic calls
Susceptible strain correctly 
classified by both readers 18/18 (100)
16/18 (89) 
(p = 0.146)
Resistant strain correctly 
classified by both readers 18/18 (100)
16/18 (89) 
(p = 0.146)
Table 3. Comparison of banding calls and diagnostic calls from two experienced readers of MTBDRplus done 
on serial dilutions of M. tuberculosis . *22 bands per strip × three dilutions × three replicates = a total of 198 
bands. P-values are for within-row comparisons between different ramp rates.
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model). We did not spike sputa with bacilli as clinical specimens from patients, which we also included, are more 
suitable (bacilli from patients in sputum are suspended in a mucous matrix rather than bubbles as they are in 
spiked sputa). Furthermore, spiking was not done at very low concentrations ( < 102 CFU/ml), where the incor-
rect ramp rate might have more of an impact, however, such concentrations of bacilli are clinically rare and often 
Xpert-negative (and hence unlikely be tested by MTBDRplus). Examination of the impact of ramp rate at lower 
concentrations might be required for tests that succeed MTBDRplus and have higher sensitivity. Finally, despite 
repeated attempts to survey a wide range of laboratories, it is possible that non-respondents may have different 
ramp rate usage patterns (e.g., due to less TB or research expertise), which may limit generalisability. This implies 
our estimated extent of incorrect ramp rate usage is an underestimate.
Our study is the first to investigate ramp rate as a cause of suboptimal MTBDRplus performance. We rec-
ommend 1) laboratories switch to the manufacturer-recommended ramp rate, 2) the manufacturer makes the 
recommended ramp rate more prominent in the documentation accompanying the assay, and 3) studies on the 
line probe assays publish the ramp rate used. Furthermore, we suggest that diagnostic laboratories who have 
conducted pilot evaluations of MTBDRplus on smear-negative specimens and found MTBDRplus to have unsat-
isfactorily high rates of non-actionable results repeat the evaluation if an incorrect ramp rate was originally used.
In conclusion, incorrect ramp rate usage is a widespread problem that negatively affects the diagnostic accu-
racy of potentially thousands of MTBDRplus assays each month. New molecular tests for drug-resistance are 
critical, however, if they are not done using the correct manufacturer-recommended conditions, performance is 
compromised and recent promising technical advances (e.g., ability to test smear-negative specimens) will not be 
fully capitalised upon. Laboratories doing MTBDRplus should hence ensure they use the correct thermocycler 
ramp rate of ≤ 2.2 °C/s.
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